Guidance, NICE advice and quality standards in development | Guidance

Showing 161 to 170 of 437

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]	Technology appraisal guidance	TBC
Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]	Technology appraisal guidance	TBC
Filgotinib for treating axial spondyloarthritis [ID6594]	Technology appraisal guidance	TBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]	Technology appraisal guidance	4 June 2026
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]	Technology appraisal guidance	TBC
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]	Technology appraisal guidance	TBC
Gantenerumab for treating early Alzheimer's disease [ID6142]	Technology appraisal guidance	TBC
Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]	Technology appraisal guidance	TBC
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain	Medical technologies guidance	TBC
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]	Technology appraisal guidance	TBC